Powerful diuretics: A common denominator in landmark hypertension and type 2 diabetes mellitus trials.
作者信息
Dasgupta Kaberi, Sapir-Pichhadze Ruth, Khan Nadia
机构信息
Department of Medicine, McGill University, Montreal, QC, Canada.
Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
出版信息
J Clin Hypertens (Greenwich). 2018 Jan;20(1):136-142. doi: 10.1111/jch.13151. Epub 2017 Dec 18.
Abstract
摘要
相似文献
1
Powerful diuretics: A common denominator in landmark hypertension and type 2 diabetes mellitus trials.
J Clin Hypertens (Greenwich). 2018 Jan;20(1):136-142. doi: 10.1111/jch.13151. Epub 2017 Dec 18.
2
Influence of a new multifactorial antihypertensive on blood pressure and metabolic profile in essential hypertension associated with non-insulin-dependent diabetes mellitus.
Eur Heart J. 1992 Jun;13 Suppl A:65-9. doi: 10.1093/eurheartj/13.suppl_a.65.
3
Risk factors as they relate to drug therapy in hypertension.
S Afr Med J. 1989 Oct 7;Suppl:8-12.
4
Treating high blood pressure in Africans with type 2 diabetes.
Ethn Dis. 2004 Winter;14(1):160-1.
5
[Revival of antihypertensive therapy: use of thiazide diuretics].
Orv Hetil. 2004 Mar 28;145(13):669-76.
6
[Hemodynamic effects of long-term saluretic therapy of hypertension].
Verh Dtsch Ges Inn Med. 1974;80:282-5.
7
Thiazides first-line treatment for hypertension.
Can Fam Physician. 2003 Jul;49:879.
8
[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
MMW Fortschr Med. 2005 Aug 4;147(31-32):43.
9
Present status of diuretics in the management of hypertension.
J Assoc Physicians India. 1998 Jul;46(7):640-4.
10
Chirally pure S-metoprolol--place in therapy.
Indian Heart J. 2010 Mar-Apr;62(2):143-5.
本文引用的文献
1
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
2
Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults.
Can J Cardiol. 2017 May;33(5):557-576. doi: 10.1016/j.cjca.2017.03.005. Epub 2017 Mar 10.
3
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
N Engl J Med. 2016 Nov 3;375(18):1799-1800. doi: 10.1056/NEJMc1611290.
4
Salt Sensitivity of Blood Pressure: A Scientific Statement From the American Heart Association.
Hypertension. 2016 Sep;68(3):e7-e46. doi: 10.1161/HYP.0000000000000047. Epub 2016 Jul 21.
5
Diuretics for Hypertension: A Review and Update.
Am J Hypertens. 2016 Oct;29(10):1130-7. doi: 10.1093/ajh/hpw030. Epub 2016 Apr 5.
6
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
N Engl J Med. 2016 May 26;374(21):2009-20. doi: 10.1056/NEJMoa1600175. Epub 2016 Apr 2.
7
Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis.
J Am Soc Hypertens. 2016 Mar;10(3):271-8. doi: 10.1016/j.jash.2016.01.009. Epub 2016 Jan 11.
8
Low Salt Diet and Insulin Resistance.
Clin Nutr Res. 2016 Jan;5(1):1-6. doi: 10.7762/cnr.2016.5.1.1. Epub 2016 Jan 29.
9
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9.
10
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
Zotero 插件